USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ADIPOGENIX, INC.
Address:
ADIPOGENIX, INC.
801 ALBANY ST, S112
BOSTON, MA 02119 0251
Phone:
(617) 638-6389
URL:
N/A
EIN:
43382537
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $499,560.00 6
SBIR Phase II $1,325,815.00 2

Award List:

ENHANCED DIFFERENTIATION OF HUMAN PREADIPOCYTES

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$99,972.00
Agency:
HHS
Principal Investigator:
Geraldine Waloga
Abstract:
Not Available The objective of Phase I is to develop and demonstrate a neural networks system to predict, map, and interpolate rotorcraft ground noise exposure data. It is well-known that the relationships between ground noise exposures. Helicopter flight paths and operation conditions are… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$99,930.00
Agency:
HHS
Principal Investigator:
Cydney C. Brooks
Abstract:
N/a

Anti-obesity drug development using human preadipocytes

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Geraldine Waloga
Abstract:
N/a

Anti-obesity drug development using human preadipocytes

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$602,471.00
Agency:
HHS
Principal Investigator:
Geraldine Waloga
Abstract:
N/a

SECRETED PROTEIN FROM ADIPOCYTES AND PREADIPOCYTES

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$99,820.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. While weight loss is the most effective treatment of type 2 diabetes, current methods for reducing weight are typically insufficient for… More

New Agents That Inhibit Fatty Acid Accumulation

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$99,894.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Although weight loss is the most effective treatment for type 2 diabetes, current methods for reducing weight typically are insufficient for… More

Activators of Adipocyte Fatty Acid Oxidation

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$99,944.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing drug and dietary treatments for obesity are only modestly effective. An approach that is very likely to be effective in treating… More

New Agents That Inhibit Fatty Acid Accumulation

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$723,344.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing treatments for obesity are only modestly effective. The mission of AdipoGenix, Inc. is to discover and develop novel therapeutics… More